'Systemic embolism' presentation slideshows

Annual Review of the LTC Literature October 1 st , 2011

Annual Review of the LTC Literature October 1 st , 2011. Dr. Robert Wells, MD, CMD Chief Medical Officer for Extended Care Physicians, PA. Chocolate Consumption Is Associated with Reduced Risk for Adverse CV Outcomes.

894 views • 77 slides

Cardioembolic Stroke

Cardioembolic Stroke. Andre Douen MD, PhD, FRCPC, FAHA Adjunct Professor, University of Ottawa, Director West GTA Regional Stroke Program, Chief, Division of Neurology, Trillium Health Centre, Mississauga. Case 1 Mrs W.S., LLM. 62 y/o obese lawyer with GERD PMH: Smoking 1ppd x 30 yrs

1.13k views • 64 slides

9th October 2013 Dr Julian Tomkinson

703 views • 52 slides

Valvular Heart Disease

Valvular Heart Disease. Basic Science March 22, 2006. 1. Information on valves may be accurately obtained by:. A. CXR B. Transthoracic echocardiography (TTE) C. Transesophageal echocardiography (TEE) D. CT scan E. Cardiac catheterization.

756 views • 50 slides

Update in Outpatient Internal Medicine

Update in Outpatient Internal Medicine. Robert A. Gluckman, MD, FACP Chief Medical Officer- Providence Health Plans March 6, 2012. Goals. PCI in stable CAD Using evidence to promote accountable care Practice variation in cardiac care Expanded use of aldosterone antagonists in CHF

614 views • 48 slides

Primary Care Education Progam

559 views • 48 slides

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors. Brief Overview of NOACs. NOACs Important Comparative Features. Effect on NOAC Plasma Levels from D-D Interactions, and Recommendations. Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.

383 views • 26 slides

A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes

A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes. C. Michael Gibson, M.S., MD. RE-LY: Study Design.

345 views • 26 slides

A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes

A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes. C. Michael Gibson, M.S., MD. RE-LY: Study Design.

323 views • 26 slides

Apixaban in Patients with Atrial Fibrillation

Apixaban in Patients with Atrial Fibrillation. AVERROES. Apixaban in Patients with Atrial Fibrillation. NEJM 10 TH FEBRUARY 2011. S tudy at 522 centers in 36 countries. Enrollment began on September 10, 2007 , and was completed on December 23, 2009 .

768 views • 24 slides

Specialized Atrial Fibrillation Clinic reduces cardiovascular morbidity and mortality in patients with atrial fibrillat

Specialized Atrial Fibrillation Clinic reduces cardiovascular morbidity and mortality in patients with atrial fibrillation. Jeroen ML Hendriks, MSc Robert G Tieleman, PhD, MD Department of Cardiology Cardiovascular Research Institute Maastricht University Medical Centre, The Netherlands

521 views • 23 slides

Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB on behalf of the ROCKET AF Investigators

R ivaroxaban O nce-daily oral direct factor Xa inhibition C ompared with vitamin K antagonism for prevention of stroke and E mbolism T rial in A trial F ibrillation. Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB on behalf of the ROCKET AF Investigators.

345 views • 21 slides

Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB on behalf of the ROCKET AF Investigators

R ivaroxaban O nce-daily oral direct factor Xa inhibition C ompared with vitamin K antagonism for prevention of stroke and E mbolism T rial in A trial F ibrillation. Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB on behalf of the ROCKET AF Investigators.

353 views • 21 slides

ARISTOTLE TRIAL

ARISTOTLE TRIAL. Dr R Nyabadza GPST1 Ward 32. Structure. AF, stroke and CHA 2 -DS 2 VASC Anticoagulant choices ARISTOTLE trial Cost NICE guidance and the future. AF and Stroke. 1-2% of general population Prevalence to double in next 50 years Increases stroke risk 5-fold

827 views • 17 slides

ASSERT Healey et al NEJM 2012;366(2):120

RAJ CHAHAL 31/01/2012. ASSERT Healey et al NEJM 2012;366(2):120. http://www.nejm.org/doi/pdf/10.1056/NEJMoa1105575. Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT).

264 views • 10 slides

Dabigatran etexilate has been shown to concurrently reduce both thrombotic and haemorrhagic events

225 views • 8 slides

Insights of the RE-LY CHA 2 DS 2 -VASc subgroup analysis Hisao Ogawa Kumamoto University, Japan

238 views • 8 slides

Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation

SPORTIF V Trial. Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation . Presented at American Heart Association Scientific Sessions 2003 Presented By Jonathan L Halperin, M.D. SPORTIF V Trial.

304 views • 6 slides

RE-LY: Primary endpoint: Stroke or systemic embolism

132 views • 1 slides

DISCUSSION / CONCLUSIONS

Literature Data Survival Models: Case Studies for Anticoagulants in Atrial Fibrillation and Acute Coronary Syndrome Farkad Ezzet Pharsight, A Certara Company, St. Louis, MO, USA. INTRODUCTION. OBJECTIVE.

109 views • 1 slides